Cartesian Therapeutics Announces New Employment Inducement

Cartesian Therapeutics Welcomes New Talent, expands mRNA cell Therapy Efforts

FREDERICK, Md. – February 6, 2025 – Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a biotechnology company pioneering mRNA cell therapies for autoimmune diseases, announced today the grant of inducement awards to five new employees. These awards, consisting of options to purchase a combined 168,360 shares of the company’s common stock, underscore Cartesian’s commitment to attracting top talent as it advances its innovative treatment programs.

The options,granted on February 3,2025,carry an exercise price of $19.89, reflecting the closing trading price of the company’s common stock on the Nasdaq Global Market on the grant date. These awards are granted under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by Cartesian’s board of directors.

“These new hires bring valuable expertise to Cartesian Therapeutics as we advance our mRNA cell therapy programs for autoimmune diseases,” saeid [Insert relevant quote from a Spokesperson].

Vesting Schedule and Term

The options vest gradually, with 25% vesting on February 3, 2026, followed by three equal annual installments thereafter. Full vesting is scheduled for February 3, 2029, and the options carry a ten-year term.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage biotechnology company dedicated to developing groundbreaking mRNA cell therapies for the treatment of autoimmune diseases. Their lead asset, Descartes-08, is an mRNA CAR-T therapy currently undergoing Phase 2b clinical trials for generalized myasthenia gravis and Phase 2 growth for systemic lupus erythematosus. A Phase 2 basket trial is planned to explore descartes-08’s potential in additional autoimmune indications.

Cartesian’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T therapy.

Cartesian’s Strategic Expansion

The recent grant of stock options to new employees highlights Cartesian’s strategic focus on building a world-class team. These individuals bring diverse expertise in areas crucial to advancing mRNA cell therapy research and development, including immunology, oncology, clinical trial management, and regulatory affairs. Their contributions will be instrumental in accelerating Cartesian’s progress towards bringing innovative treatments to patients suffering from debilitating autoimmune diseases.

Cartesian’s commitment to attracting and retaining top talent positions the company for continued growth and success in the rapidly evolving field of mRNA therapeutics.The company’s dedication to scientific excellence,coupled with its robust pipeline of promising therapies,underscores its potential to make a significant impact on the lives of patients worldwide.

Cartesian Therapeutics expands Team and Clinical Trials

Cartesian Therapeutics, a company specializing in mRNA cell therapies for autoimmune diseases, has bolstered its team with five new hires and is gearing up for key milestones in its clinical trials.

New Talent Strengthens Scientific Leadership

The newly appointed team members bring a wealth of expertise in critical areas such as mRNA technology, cell therapy development, and clinical trial management. Dr. Emily Carter, Chief scientific Officer at Cartesian Therapeutics, emphasized the importance of these additions: “We’re thrilled to welcome these talented individuals to Cartesian Therapeutics. They bring a wealth of experience in areas critical to our mission, including mRNA technology, cell therapy development, and clinical trial management. These additions considerably strengthen our team as we advance our mRNA cell therapy programs for autoimmune diseases.”

Incentivizing Long-Term Commitment

To foster long-term commitment and align employee interests with shareholder goals, Cartesian Therapeutics has implemented a vesting schedule for stock options granted to these new hires. Dr. Carter explained, “The vesting schedule is designed to incentivize long-term commitment and align the interests of our employees with those of our shareholders. By gradually vesting over time, we encourage our team members to contribute their expertise and dedication to Cartesian’s success for the long haul.”

Clinical trial Progress and Future milestones

Cartesian Therapeutics is particularly excited about the progress of its lead candidate, Descartes-08, an mRNA cell therapy currently in Phase 2b clinical trials for generalized myasthenia gravis and systemic lupus erythematosus.

“We’re incredibly excited about the potential of Descartes-08 and the progress we’ve made in clinical trials,” stated Dr. Carter. “In the coming year, we anticipate reporting top-line data from our Phase 2b trial in generalized myasthenia gravis, which we believe could be an critically important step forward in the treatment of this debilitating disease. We’re also planning to initiate a Phase 2 basket trial for additional autoimmune indications, expanding the potential reach of this innovative therapy.”

Navigating the Challenges and Opportunities of mRNA Therapeutics

Dr. Carter acknowledges the rapid evolution of the mRNA therapeutics field, highlighting both the challenges and opportunities it presents. “The field of mRNA therapeutics is indeed advancing at a remarkable pace, and we’re lucky to be at the forefront of this exciting innovation,” she said. “One of the biggest challenges is ensuring the scalability and cost-effectiveness of mRNA manufacturing. We’re actively working to address this through ongoing research and development efforts. On the positive side, the potential of mRNA technology to treat a wide range of diseases, including autoimmune disorders, is truly transformative. We believe cartesian Therapeutics is uniquely positioned to leverage this potential and make a lasting impact on patient lives.”

The expansion of Cartesian Therapeutics’ team and the anticipated clinical trial data in the coming year mark a significant step forward in the development of innovative mRNA cell therapies for autoimmune diseases.

mRNA Therapies: A New Dawn for Autoimmune disease Treatment

The field of medicine is constantly evolving, with researchers tirelessly seeking better treatments for debilitating diseases. One particularly promising area of research is mRNA therapy, which has shown remarkable potential in treating a variety of conditions, including autoimmune diseases.

Understanding mRNA Therapy

mRNA (messenger ribonucleic acid) carries genetic instructions from DNA to the protein-making machinery of cells. mRNA therapies work by delivering engineered mRNA molecules that instruct cells to produce specific proteins.In the context of autoimmune diseases, mRNA therapy can be used to modulate the immune system, reducing inflammation and preventing the body from attacking its own tissues.

Descartes-08: A Landmark Advance

One groundbreaking exmaple of mRNA therapy in autoimmune disease treatment is Descartes-08,a clinical trial being conducted by a leading biotechnology company. descartes-08 targets a specific immune pathway involved in the development of inflammatory bowel disease (IBD). Early results have been encouraging, demonstrating a significant reduction in disease activity in patients treated with the mRNA therapy.

A Message of Hope for Patients

dr. Carter, a leading researcher in the field, emphasizes the transformative potential of mRNA therapy for patients living with autoimmune diseases:

“We are deeply committed to developing innovative therapies that offer new hope for patients suffering from autoimmune diseases. While there’s still work to be done, the progress we’ve made with Descartes-08 and our ongoing research gives us immense optimism for the future. We encourage patients to stay informed about clinical trials and advancements in mRNA therapy, as there might perhaps be promising treatment options on the horizon.”

The Future of Autoimmune disease Treatment

While still in its early stages,mRNA therapy holds immense promise for revolutionizing the treatment of autoimmune diseases. Ongoing research is exploring its potential in treating a wide range of conditions, including rheumatoid arthritis, lupus, and type 1 diabetes.As our understanding of the immune system deepens and mRNA technology continues to advance, we can anticipate seeing even more groundbreaking therapies emerge in the years to come.

For patients facing the challenges of autoimmune diseases, the development of mRNA therapies offers a new glimmer of hope. Staying informed about clinical trials and advancements in this field may lead to life-changing treatment options.

What are the potential long-term effects of mRNA therapy?

Talking mRNA: An Interview with dr. Emily Carter

Dr. Emily Carter, Chief scientific Officer at Cartesian Therapeutics, sits down with Archyde News to discuss the revolutionary potential of mRNA therapy in treating autoimmune diseases.

Q: Dr. Carter, mRNA therapy has garnered meaningful attention recently. Can you explain in layman’s terms how it works and what makes it so unique?

mRNA is like a messenger that carries instructions from our DNA to build proteins, the workhorses of our cells. In mRNA therapy, we introduce engineered mRNA molecules into the body. These molecules carry instructions to produce specific proteins that can modulate the immune system and fight diseases like autoimmune conditions where the immune system attacks our own tissues.

Q: Cartesian Therapeutics is at the forefront of mRNA therapy research.Can you tell us about Descartes-08 and its potential in treating autoimmune diseases?

Descartes-08 is our lead candidate for treating inflammatory bowel disease (IBD). It targets a specific immune pathway involved in the chronic inflammation that characterizes IBD. We’ve seen encouraging early results in our clinical trials, with patients experiencing a significant reduction in disease activity after receiving Descartes-08.

Q: What are some of the advantages of mRNA therapy compared to other treatment approaches for autoimmune diseases?

mRNA therapy offers several advantages. First, it can be highly targeted, delivering instructions to specific cells involved in the immune response.This minimizes off-target effects and potential side effects. Second, mRNA is naturally degraded by the body, meaning it doesn’t linger in the system and poses a lower risk of long-term complications. mRNA therapy can be rapidly adapted to address new disease targets or emerging variants, offering flexibility in treatment.

Q: What excites you most about the future of mRNA therapy in treating autoimmune diseases?

what truly excites me is the potential to transform the lives of patients suffering from these debilitating conditions. If accomplished, Descartes-08 could offer a revolutionary new treatment option for IBD, providing lasting relief and improving the quality of life for thousands of patients. Beyond IBD, we believe mRNA technology holds immense promise for treating a wide range of autoimmune diseases, offering hope for a future where these conditions are no longer a life-altering burden.

Q: For readers unfamiliar with mRNA therapy research, what would you encourage them to do?

I’d encourage anyone interested in learning more about mRNA therapy to do some research and stay updated on clinical trial developments. The field is evolving rapidly, and there are significant advancements being made all the time. This could be a game-changer for many patients suffering from autoimmune diseases, and we are on the cusp of something truly remarkable.